Jazz Pharmaceuticals delivered a strong Q1 FY2026 with revenue up 19.1% YoY to $1.07B and a sharp swing to profitability, posting net income of $293.1M versus a -$92.5M loss a year ago. The balance sheet shows $1.84B cash against $5.35B long-term debt, with no dilution events in the past 12 months.
•Revenue grew 19.1% YoY to $1.07B, accelerating from $897.8M in Q1 FY2025.
•Net income swung to $293.1M from a -$92.5M loss, with diluted EPS of $4.43 vs. -$1.52; the large YoY improvement partly reflects a weak prior-year quarter.
•Balance sheet: $1.84B cash, $5.35B long-term debt, and $4.53B equity; debt-to-equity ratio of 1.18x, indicating moderate leverage.
•No dilution events in the past 12 months; recent filings include routine proxy and officer changes, no capital raises.
Informational summary based on SEC XBRL figures · generated by AI agent. Not investment advice.
An Ireland-based specialty biopharmaceutical company that makes Epidiolex — the world's first FDA-approved cannabis-derived prescription medicine — alongside a broader CNS, sleep, and oncology drug portfolio.
💊 Epidiolex (pharmaceutical-grade CBD) is FDA-approved for Dravet syndrome and Lennox-Gastaut — a $500M+ annual revenue product
🧬 Broader portfolio (Xyrem, Xywav, Rylaze) provides revenue stability well beyond the cannabis-derived drug
🏛️ Regulated pharma model means Jazz carries none of the federal conflict risk facing plant-touching cannabis companies
What does Jazz Pharmaceuticals do, and what is its main cannabis-related product?
Jazz Pharmaceuticals is an Ireland-based specialty biopharmaceutical company that develops and commercializes therapies in neuroscience, sleep medicine, and oncology. Its most notable cannabis-related product is Epidiolex, the world's first FDA-approved prescription medicine derived from cannabis. Epidiolex is a pharmaceutical-grade cannabidiol (CBD) formulation approved for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, two rare and severe forms of epilepsy. Epidiolex generates over $500 million in annual revenue, making it a significant player in the cannabis-derived pharmaceutical space. Unlike plant-touching cannabis companies, Jazz operates under a regulated pharmaceutical model, which eliminates federal legal risks.
What is Jazz Pharmaceuticals' business model, and how does it differ from typical cannabis companies?
Jazz Pharmaceuticals operates as a regulated specialty biopharmaceutical company, focusing on research, development, and commercialization of prescription medicines. Its business model is built on a diversified portfolio that includes both cannabis-derived drugs like Epidiolex and non-cannabis therapies such as Xyrem, Xywav, and Rylaze for narcolepsy, idiopathic hypersomnia, and oncology, respectively. This diversification provides revenue stability beyond cannabis. Unlike most cannabis companies that are plant-touching and face federal illegality in the U.S., Jazz's pharmaceutical model means it carries none of the federal conflict risk. The company generates revenue through prescription sales, insurance reimbursements, and partnerships, with a strong emphasis on clinical trials and regulatory approvals.
How does Jazz Pharmaceuticals fit into the cannabis sector?
Jazz Pharmaceuticals is categorized as a cannabis-related pharmaceutical and biotech company on WeedMarketCap. It occupies a unique niche in the cannabis sector because its primary cannabis product, Epidiolex, is a FDA-approved prescription medicine derived from cannabis, rather than a recreational or unregulated product. This positions Jazz as a bridge between the pharmaceutical industry and the cannabis market. Unlike MSOs (multi-state operators) or Canadian LPs that cultivate and sell cannabis flower or extracts, Jazz focuses on high-barrier, regulated drug development. Its role is more akin to a traditional biotech firm, leveraging cannabis compounds for therapeutic applications. This model offers investors exposure to cannabis-derived pharmaceuticals without the regulatory risks faced by plant-touching companies.
What are the key differentiators of Jazz Pharmaceuticals in the cannabis space?
Jazz Pharmaceuticals' key differentiators include its FDA-approved cannabis-derived medicine Epidiolex, which is the first and only such drug on the market, targeting rare epilepsy syndromes. The product generates over $500 million in annual revenue, showcasing commercial success. Additionally, Jazz's broader portfolio of non-cannabis drugs like Xyrem, Xywav, and Rylaze provides revenue diversification and stability, reducing reliance on cannabis-derived products. The company's regulated pharmaceutical model eliminates federal legal risks that plague plant-touching cannabis companies. Furthermore, Jazz's Ireland-based headquarters and global operations allow it to navigate international regulatory landscapes. These factors make Jazz a distinct, lower-risk entry point for investors interested in cannabis-related pharmaceuticals.
What markets does Jazz Pharmaceuticals serve, and where is it headquartered?
Jazz Pharmaceuticals is headquartered in Ireland, but it operates globally as a specialty biopharmaceutical company. Its products are marketed primarily in the United States, Europe, and other international markets. Epidiolex, its cannabis-derived drug, is approved in the U.S. for Dravet syndrome and Lennox-Gastaut syndrome, and it has also received approvals in several European countries for similar indications. The company's broader portfolio, including sleep and oncology drugs, is sold across multiple regions. While specific market details are limited in the provided data, Jazz's global footprint allows it to serve patients worldwide. Its Ireland base provides a favorable corporate tax environment, but its commercial operations are heavily focused on the U.S., the largest pharmaceutical market.
